Natera, Inc. presented a comprehensive set of new data at the 2025 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI). The presentations highlighted Signatera’s capabilities and introduced initial results for a novel tissue-free MRD detection test.
Data from the BESPOKE CRC study, a prospective, observational study in colorectal cancer, showed that post-surgical Signatera-positivity was highly predictive of inferior outcomes in stage II and stage III patients. Specifically, 24-month disease-free survival estimates for stages II-III combined were 91.7% for Signatera-negative and 41.4% for Signatera-positive patients.
Initial results from Natera’s novel tissue-free molecular residual disease (MRD) detection test demonstrated high sensitivity and specificity in patients evaluable for clinical outcomes. The study also showed strong concordance between the tissue-free MRD test and the gold standard Signatera test, with a positive percent agreement of 86% and a negative percent agreement of 98%.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.